The high-stakes patent war between CAR-T giants Gilead Sciences and Bristol Myers Squibb isn’t over just yet. After an appeals court overturned a $1.2 billion verdict against Gilead, BMS is asking the United States’ top court to take another look.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,